Fu Yifan, Tao Jinxin, Gu Yani, Liu Yueze, Qiu Jiangdong, Su Dan, Wang Ruobing, Luo Wenhao, Liu Tao, Zhang Feifan, Zhang Taiping, Zhao Yupei
General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
4 + 4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
NPJ Precis Oncol. 2024 May 20;8(1):109. doi: 10.1038/s41698-024-00586-x.
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm characterized by a poor prognosis and limited therapeutic strategy. The PDAC tumor microenvironment presents a complex heterogeneity, where neutrophils emerge as the predominant constituents of the innate immune cell population. Leveraging the power of single-cell RNA-seq, spatial RNA-seq, and multi-omics approaches, we included both published datasets and our in-house patient cohorts, elucidating the inherent heterogeneity in the formation of neutrophil extracellular traps (NETs) and revealed the correlation between NETs and immune suppression. Meanwhile, we constructed a multi-omics prognostic model that suggested the patients exhibiting downregulated expression of NETs may have an unfavorable outcome. We also confirmed TLR2 as a potent prognosis factor and patients with low TLR2 expression had more effective T cells and an overall survival extension for 6 months. Targeting TLR2 might be a promising strategy to reverse immunosuppression and control tumor progression for an improved prognosis.
胰腺导管腺癌(PDAC)是一种高度恶性的肿瘤,其特点是预后差且治疗策略有限。PDAC肿瘤微环境呈现出复杂的异质性,其中中性粒细胞是先天免疫细胞群体的主要组成部分。利用单细胞RNA测序、空间RNA测序和多组学方法的优势,我们纳入了已发表的数据集和我们内部的患者队列,阐明了中性粒细胞胞外陷阱(NETs)形成过程中的内在异质性,并揭示了NETs与免疫抑制之间的相关性。同时,我们构建了一个多组学预后模型,表明NETs表达下调的患者可能预后不良。我们还证实TLR2是一个有效的预后因素,TLR2表达低的患者有更有效的T细胞,总生存期延长6个月。靶向TLR2可能是一种有前景的策略,可逆转免疫抑制并控制肿瘤进展以改善预后。
Cancer Res. 2021-7-1
Ann Surg Oncol. 2018-10-29
Front Med (Lausanne). 2025-7-23
Br J Cancer. 2025-6-2
Pharmaceuticals (Basel). 2025-1-10
J Exp Clin Cancer Res. 2024-10-3
Nat Rev Cancer. 2023-7
Cell. 2023-4-13
Nat Rev Clin Oncol. 2023-5
Sci Transl Med. 2023-3-15